SFDA Announces Registration of Skyclarys for Treatment of Rare Genetic Neurological Disorder
Riyadh: The Saudi Food and Drug Authority (SFDA) has approved the registration of Skyclarys (Omaveloxolone), which was previously designated as an orphan drug under the SFDA Orphan Drug Program. The medication is indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older, a rare